Bavarian Nordic Publishes Annual Report 2023 - Seite 2
original, 15-Feb-2023
latest, 03-Aug-2023
Audited
Outlook for 2024
For 2024, Bavarian Nordic expects revenue of DKK 5,000-5,300 million and EBITDA of DKK 1,100-1,350 million.
The expected revenue is comprised of DKK 2,700–3,000 million from Public Preparedness vaccines, of which DKK 1,600 million have already been secured by contracts, approximately DKK 2,100 million from Travel Health vaccines and approximately DKK 200 million from contract work.
The financial guidance is unchanged compared to the guidance stated on February 21, 2024 in company announcement no. 01/2024, which contains a full description of assumptions for the guidance, also available in the annual report.
Conference call and webcast
The management of Bavarian Nordic will host a conference call today at 2:00 pm CET (8:00 am EST) to present the full-year results followed by a Q&A session. A listen-only version of the call
and presentation slides can be accessed via https://bit.ly/bavaFY2023. To join the Q&A session, please register in advance via https://bit.ly/bavaFY2023reg.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to
governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com.
Lesen Sie auch
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or
other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made,
except as required by law.